Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tazarotene

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Tazarotene. Displaying page 1 of 1.
    EudraCT Number: 2004-004825-87 Sponsor Protocol Number: R00002 VE 201 Start Date*: 2005-04-22
    Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
    Full Title: Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups.
    Medical condition: Psoriasis of the skin is frequently accompanied by nail changes: between 10 and 78% of psoriatic patients suffer from changes of the nails. More than 50% of patients with nail psoriasis have pain b...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028703 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-004519-28 Sponsor Protocol Number: H573000-1307 Start Date*: 2013-12-20
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group comparison
    Medical condition: patients with mild to moderate nail psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006878-22 Sponsor Protocol Number: R00002 CR 201 (ORF) Start Date*: 2007-12-11
    Sponsor Name:Orfagen
    Full Title: Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.
    Medical condition: Lamellar Ichthyosis (LI)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001474-27 Sponsor Protocol Number: Baceca-030-BCC Start Date*: 2005-07-07
    Sponsor Name:TopoTarget A/S
    Full Title: A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma
    Medical condition: skin cancer of the type of Basal Cell Carcinoma (BCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004900-44 Sponsor Protocol Number: SF114570 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl peroxide/Clindamycin gel and Tazarotene cream when used in combination in the Treat...
    Medical condition: Acne Vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018355-10 Sponsor Protocol Number: H553000-1001 Start Date*: 2010-06-18
    Sponsor Name:Almirall Hermal GmbH
    Full Title: An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Two Active Controls in a Psoriasis-P...
    Medical condition: Plaque-type psoriasis (psoriasis vulgaris) for at least 6 months
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001384-45 Sponsor Protocol Number: H553000-1101 Start Date*: 2011-06-29
    Sponsor Name:Almirall Hermal GmbH
    Full Title: A 22 day bland ointment and reference-controlled, investigator-blind, single center, randomized, proof of concept clinical study with an intraindividual comparison investigating the anti-psoriatic ...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022284-35 Sponsor Protocol Number: R00002 CR 301 (ORF) Start Date*: 2011-03-08
    Sponsor Name:ORFAGEN
    Full Title: CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI)
    Medical condition: Lamellar Ichthyosis (LI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023686 LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) DE (Completed) FR (Ongoing) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024214-54 Sponsor Protocol Number: RD.03.SPR.40129 Start Date*: 2011-04-28
    Sponsor Name:GALDERMA R&D SNC
    Full Title: Exploratory study to assess facial tolerability after daily application of several concentrations and formulations containing CD5789 in acne subjects
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-003336-72 Sponsor Protocol Number: 81413F Start Date*: 2013-10-30
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLGIA
    Full Title: A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC)
    Medical condition: BASAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022211-19 Sponsor Protocol Number: RD.03.SPR.40126 Start Date*: 2011-01-07
    Sponsor Name:GALDERMA R&D
    Full Title: PILOT STUDY TO EXPLORE EFFICACY AND SAFETY OF DIFFERENT DOSE REGIMENS OF CD5789 IN SUBJECTS WITH ACNE VULGARIS
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2008-006227-31 Sponsor Protocol Number: 0881X1-4503 Start Date*: 2009-01-09
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment
    Medical condition: Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. Th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002406-43 Sponsor Protocol Number: V01-118A-401 Start Date*: 2020-07-31
    Sponsor Name:Bausch Health Americas, Inc.(affiliate of Bausch Health US , LLC, formerly known as Dow Pharmaceutical Sciences)
    Full Title: A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion i...
    Medical condition: Moderate to severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000186-13 Sponsor Protocol Number: H553000-1006 Start Date*: 2011-04-14
    Sponsor Name:Almirall Hermal GmbH
    Full Title: An Investigator-blind, Controlled Exploratory Study to Assess the Efficacy and Safety of Different Concentrations of Active Ingredients in the project Formulations of LAS 41004 Compared to a Bland ...
    Medical condition: Plaque-type psoriasis (psoriasis vulgaris) for at least 12 months
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001697-26 Sponsor Protocol Number: 055-006 Start Date*: 2011-12-12
    Sponsor Name:Professor Reich
    Full Title: Optimising outpatient care in mild to moderate psoriasis by a newly developed ‘Topical Treatment Optimising Programme’ - an international study using Daivobet®/Dovobet® Gel (‘PSO-TOP’)
    Medical condition: Mild to moderate active plaque psoriasis despite topical psoriasis treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IT (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004765-90 Sponsor Protocol Number: DFD03-CD-004 Start Date*: 2016-07-13
    Sponsor Name:Dr. Reddy’s Laboratories, Ltd
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
    Medical condition: Acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023901-36 Sponsor Protocol Number: UHK-GMD-LOA-04 Start Date*: 2011-04-12
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University, Magdeburg
    Full Title: Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study) - as an interventional observation study (phase IV) within approved label and indication and with minimal invasive taking of ski...
    Medical condition: STELARA™ as IMP will be used in all relevant aspects (indication, contraindications, dosing) completely within the approved label, namely for the treatment of adult patients with moderate to severe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018517-29 Sponsor Protocol Number: DMD-UHK-B1 Start Date*: 2010-02-22
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.
    Medical condition: Fumaderm initial / Fumaderm will be used in this CT completely "in-label", i.e. for the treatment of adult patients of both genders with moderate to severe plaque psoriasis in so far as a solely to...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 00:45:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA